Mississippi Delta Health Collaborative MTM Program: In-State School of Pharmacy Partnership for Implementation Support and Community–Clinical Linkages

The Mississippi State Department of Health is seeking an in-state School of Pharmacy partner to provide implementation support for the Mississippi Delta Health Collaborative (MDHC) Community Pharmacy Medication Therapy Management (MTM) Program. The selected partner will collaborate with MDHC to strengthen community-clinical linkages, support training and engagement of pharmacists and interprofessional healthcare teams, participate in the MDHC MTM Advisory Task Force and the Mississippi Alliance for Cardiovascular Health (MACH) Learning Collaborative, assist with community outreach and screening activities, and support dissemination of program outcomes and best practices. The partner will also contribute to workforce development by creating and supporting pharmacy student and resident learning experiences focused on rural health, public health practice, chronic disease prevention, and population health strategies. Some key requirements for applicants include: • Being a non-federal entity, as set forth in 45 CFR 75 or 2 CFR 200.69 • Being an in-state School of Pharmacy that is fully accredited by the Accreditation Council for Pharmacy Education (ACPE) • Having experience in providing pharmacy education, training, and experiential learning opportunities for PharmD students and/or pharmacy residents • Having experience in community-based or population health initiatives, particularly those focused on chronic disease prevention and management • Having experience in supporting interprofessional education or collaborative practice models involving pharmacists and other healthcare providers • Having experience in conducting or contributing to implementation, evaluation, or quality improvement activities in healthcare or public health settings • Having experience working with rural populations, preferably with demonstrated experience in addressing health outcomes related to cardiovascular disease, hypertension, or high cholesterol The total available funding is up to $200,000 annually, with an estimated total award amount of up to $600,000 through September 29, 2029, contingent upon funding availability and satisfactory performance.